|Day's Range||25.72 - 25.89|
|52 Week Range||19.96 - 26.35|
|PE Ratio (TTM)||39.27|
|Dividend & Yield||0.78 (3.03%)|
|1y Target Est||N/A|
In 2016, AbbVie’s (ABBV) Lupron generated revenue of $821 million, a slight fall of 0.6% year-over-year (or YoY). In 1Q17, Lupron reported revenue of ~$194 million.
Amgen’s (AMGN) Kyprolis has gained considerable market share in second-line multiple myeloma (or MM) indication since its launch in 2012.
BiomX, which is developing drugs using microbiome bacteria, said on Monday it raised $24 million in an early stage funding round led by OrbiMed, Jonhnson & Johnson Innovation and Takeda Ventures. Seventure ...